X0306 4 2018-04-02 1 0001661998 Homology Medicines, Inc. FIXX 0001021944 Temasek Holdings (Private) Ltd 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD SINGAPORE U0 238891 SINGAPORE 0 0 1 0 0001379348 Fullerton Management Pte Ltd 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD SINGAPORE U0 238891 SINGAPORE 0 0 1 0 0001379349 Temasek Life Sciences Private Ltd 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD SINGAPORE U0 238891 SINGAPORE 0 0 1 0 0001673754 TLS Beta Pte. Ltd. 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD SINGAPORE U0 238891 SINGAPORE 0 0 1 0 0001379350 V-Sciences Investments Pte Ltd 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD SINGAPORE U0 238891 SINGAPORE 0 0 1 0 Common Stock 2018-04-02 4 C 0 1605681 A 1605681 I See footnote Common Stock 2018-04-02 4 C 0 989612 A 2595293 I See footnote Common Stock 2018-04-02 4 P 0 625000 16.00 A 3220293 I See footnote Series A Preferred Stock 2018-04-02 4 C 0 1605681 D Common Stock 1605681 0 I See footnotes Series B Preferred Stock 2018-04-02 4 C 0 989612 D Common Stock 989612 0 I See footnotes The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. Consists of 1,605,681 shares of Common Stock held of record by TLS Beta. Consists of 989,612 shares of Common Stock held of record by TLS Beta. Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences. TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Temasek Holdings (Private) Limited, By: /s/Christina Choo, Authorized Signatory 2018-04-04 Fullerton Management Pte Ltd, By: /s/ Cheong Kok Tim, Director 2018-04-04 Temasek Life Sciences Private Limited, By: /s/ Lim Siew Lee Sherlyn, Director 2018-04-04 TLS Beta Pte. Ltd., By: /s/ Christina Choo, Director 2018-04-04 V-Sciences Investments Pte Ltd, By: /s/ Christina Choo, Director 2018-04-04